Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy

Implications for the design of future non-small-cell lung cancer combined modality trials

Katherine M W Pisters, Mark G. Kris, Richard J. Gralla, Muhammed B. Zaman, Robert T. Heelan, Nael Martini

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Purpose: This report determines the incidence of pathologic complete response in patients with locally advanced non-small-cell lung cancer (NSCLC) treated with mitomycin, vinca alkaloid, and high-dose cisplatin (MVP) chemotherapy, and estimates the effect of MVP on survival. Patients and Methods: We have identified and reviewed the course of 21 patients with advanced NSCLC who achieved a pathologic complete response following a median of three preoperative MVP combination chemotherapy courses including vinblastine or vindesine, cisplatin (120 mg/m2), and mitomycin (n = 19). Results: All patients had a major objective response following preoperative chemotherapy and nine (43%) had a clinical complete response. Nine patients with pathologic complete responses were among 73 entered on a preoperative chemotherapy program, yielding an incidence estimate of 12% (95% confidence interval, 6% to 22%). The median survival duration for all 21 patients has not been reached. The median follow-up duration is now 68 months (range, 17 to 109). Survival estimates are 90% at 1 year, 62% at 3 years, and 54% at 5 years. Nine patients have relapsed with initial sites of recurrence as follows: brain (n = 5), other systemic sites (n = 3), and locoregional (n = 1). One patient died in the postoperative period. Eleven patients remain disease-free and all have excellent functional status. Conclusion: We have observed pathologic complete responses in approximately 12% of advanced NSCLC patients treated with preoperative MVP chemotherapy. These pathologically determined responses were seen only in patients with major objective responses clinically. Pathologic complete response predicts excellent survival and functional level and should be considered a major end point in the evaluation of preoperative chemotherapy programs.

Original languageEnglish (US)
Pages (from-to)1757-1762
Number of pages6
JournalJournal of Clinical Oncology
Volume11
Issue number9
StatePublished - 1993
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Drug Therapy
Survival
Mitomycin
Cisplatin
Vindesine
Vinca Alkaloids
Vinblastine
Incidence
Combination Drug Therapy
Postoperative Period
Confidence Intervals
Recurrence
Brain

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy : Implications for the design of future non-small-cell lung cancer combined modality trials. / Pisters, Katherine M W; Kris, Mark G.; Gralla, Richard J.; Zaman, Muhammed B.; Heelan, Robert T.; Martini, Nael.

In: Journal of Clinical Oncology, Vol. 11, No. 9, 1993, p. 1757-1762.

Research output: Contribution to journalArticle

@article{2238c4183c2443e2a493509d314c261e,
title = "Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: Implications for the design of future non-small-cell lung cancer combined modality trials",
abstract = "Purpose: This report determines the incidence of pathologic complete response in patients with locally advanced non-small-cell lung cancer (NSCLC) treated with mitomycin, vinca alkaloid, and high-dose cisplatin (MVP) chemotherapy, and estimates the effect of MVP on survival. Patients and Methods: We have identified and reviewed the course of 21 patients with advanced NSCLC who achieved a pathologic complete response following a median of three preoperative MVP combination chemotherapy courses including vinblastine or vindesine, cisplatin (120 mg/m2), and mitomycin (n = 19). Results: All patients had a major objective response following preoperative chemotherapy and nine (43{\%}) had a clinical complete response. Nine patients with pathologic complete responses were among 73 entered on a preoperative chemotherapy program, yielding an incidence estimate of 12{\%} (95{\%} confidence interval, 6{\%} to 22{\%}). The median survival duration for all 21 patients has not been reached. The median follow-up duration is now 68 months (range, 17 to 109). Survival estimates are 90{\%} at 1 year, 62{\%} at 3 years, and 54{\%} at 5 years. Nine patients have relapsed with initial sites of recurrence as follows: brain (n = 5), other systemic sites (n = 3), and locoregional (n = 1). One patient died in the postoperative period. Eleven patients remain disease-free and all have excellent functional status. Conclusion: We have observed pathologic complete responses in approximately 12{\%} of advanced NSCLC patients treated with preoperative MVP chemotherapy. These pathologically determined responses were seen only in patients with major objective responses clinically. Pathologic complete response predicts excellent survival and functional level and should be considered a major end point in the evaluation of preoperative chemotherapy programs.",
author = "Pisters, {Katherine M W} and Kris, {Mark G.} and Gralla, {Richard J.} and Zaman, {Muhammed B.} and Heelan, {Robert T.} and Nael Martini",
year = "1993",
language = "English (US)",
volume = "11",
pages = "1757--1762",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy

T2 - Implications for the design of future non-small-cell lung cancer combined modality trials

AU - Pisters, Katherine M W

AU - Kris, Mark G.

AU - Gralla, Richard J.

AU - Zaman, Muhammed B.

AU - Heelan, Robert T.

AU - Martini, Nael

PY - 1993

Y1 - 1993

N2 - Purpose: This report determines the incidence of pathologic complete response in patients with locally advanced non-small-cell lung cancer (NSCLC) treated with mitomycin, vinca alkaloid, and high-dose cisplatin (MVP) chemotherapy, and estimates the effect of MVP on survival. Patients and Methods: We have identified and reviewed the course of 21 patients with advanced NSCLC who achieved a pathologic complete response following a median of three preoperative MVP combination chemotherapy courses including vinblastine or vindesine, cisplatin (120 mg/m2), and mitomycin (n = 19). Results: All patients had a major objective response following preoperative chemotherapy and nine (43%) had a clinical complete response. Nine patients with pathologic complete responses were among 73 entered on a preoperative chemotherapy program, yielding an incidence estimate of 12% (95% confidence interval, 6% to 22%). The median survival duration for all 21 patients has not been reached. The median follow-up duration is now 68 months (range, 17 to 109). Survival estimates are 90% at 1 year, 62% at 3 years, and 54% at 5 years. Nine patients have relapsed with initial sites of recurrence as follows: brain (n = 5), other systemic sites (n = 3), and locoregional (n = 1). One patient died in the postoperative period. Eleven patients remain disease-free and all have excellent functional status. Conclusion: We have observed pathologic complete responses in approximately 12% of advanced NSCLC patients treated with preoperative MVP chemotherapy. These pathologically determined responses were seen only in patients with major objective responses clinically. Pathologic complete response predicts excellent survival and functional level and should be considered a major end point in the evaluation of preoperative chemotherapy programs.

AB - Purpose: This report determines the incidence of pathologic complete response in patients with locally advanced non-small-cell lung cancer (NSCLC) treated with mitomycin, vinca alkaloid, and high-dose cisplatin (MVP) chemotherapy, and estimates the effect of MVP on survival. Patients and Methods: We have identified and reviewed the course of 21 patients with advanced NSCLC who achieved a pathologic complete response following a median of three preoperative MVP combination chemotherapy courses including vinblastine or vindesine, cisplatin (120 mg/m2), and mitomycin (n = 19). Results: All patients had a major objective response following preoperative chemotherapy and nine (43%) had a clinical complete response. Nine patients with pathologic complete responses were among 73 entered on a preoperative chemotherapy program, yielding an incidence estimate of 12% (95% confidence interval, 6% to 22%). The median survival duration for all 21 patients has not been reached. The median follow-up duration is now 68 months (range, 17 to 109). Survival estimates are 90% at 1 year, 62% at 3 years, and 54% at 5 years. Nine patients have relapsed with initial sites of recurrence as follows: brain (n = 5), other systemic sites (n = 3), and locoregional (n = 1). One patient died in the postoperative period. Eleven patients remain disease-free and all have excellent functional status. Conclusion: We have observed pathologic complete responses in approximately 12% of advanced NSCLC patients treated with preoperative MVP chemotherapy. These pathologically determined responses were seen only in patients with major objective responses clinically. Pathologic complete response predicts excellent survival and functional level and should be considered a major end point in the evaluation of preoperative chemotherapy programs.

UR - http://www.scopus.com/inward/record.url?scp=0027323229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027323229&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 1757

EP - 1762

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -